Oral insulin and buccal insulin: A critical reappraisal

Journal of Diabetes Science and Technology

Volumn 3, Issue 3, 2009, Pages 568-584

  Heinemann, Lutz ^a   Jacques, Yves ^b  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b Upsilon Pharma Consulting   (France)

Author keywords

Buccal insulin; Insulin formulations; Insulin therapy; Oral insulin

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ANIMAL; BUCCAL DRUG ADMINISTRATION; DIABETES MELLITUS; DISEASE MODEL; DOG; HUMAN; ORAL DRUG ADMINISTRATION; RAT; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, BUCCAL; ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; RATS; TREATMENT OUTCOME;

EID: 75649141158     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229680900300323     Document Type: Review

References (38)

1. Heinemann L. The failure of Exubera: are we beating a dead horse? J Diabetes Sci Technol. 2008;2(3):518-29.
2. Pettis RJ, Hompesch M, Kapitza C, Harvey NG, Ginsberg B, Heinemann L. Intra-dermal insulin lispro application with a new microneedle delivery system led to a substantially more rapid insulin absorption than subcutaneous injection. Diabetes. 2006;55(Suppl 1):A26.
3. Carino GP, Mathiowitz E. Oral insulin delivery. Adv Drug Deliv Rev. 1999;35(2-3):249-57.
4. Lassmann-Vague V, Raccah D. Alternative routes of insulin delivery. Diabetes Metab. 2006;32(5 Pt 2):513-22.
5. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med. 2003;20(11):886-98.
6. Sadrzadeh N, Glembourtt MJ, Stevenson CL. Peptide drug delivery strategies for the treatment of diabetes. J Pharm Sci. 2007;96(8):1925-54.
7. Khafagy el-S, Morishita M, Onuki Y, Takayama K. Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev. 2007;59(15):1521-46.
8. Berger M. Oral insulin 1922-1992: the history of continuous ambition and failure. In: Frontiers in insulin pharmacology. Berger M, Gries FA, eds. Germany: Thieme Publishing Group; 1993. pp. 144-8.
9. Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. Diabetes Care. 2004;27(12):2868-73.
10. Kidron M, Dinh S, Menachem Y, Abbas R, Variano B, Goldberg M, Arbit E, Bar-On H. A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet Med. 2004;21(4):354-7.
11. Kapitza C, Arbit E, Abbas R, Goldberg M, Hompesch M, Heinemann L, Heise T. Oral insulin: proof of concept in type 2 diabetes patients. Diabetes. 2003;52(Suppl 1):A37.
12. Heise T, Kapitza C, Nosek L, Becket P, Gelfand R, Goldberg M, Arbit E. Oral insulin as first-line therapy in type 2 diabetes: a randomized controlled pilot study. Diabetologia. 2004;47(Suppl 1):A5.
13. Heise T, Nosek L, Arbit E, Beckett P, Gelfand R, Porter KM, Goldberg M, Kapitza C. Reduction of postprandial blood glucose excursions by an optimized formulation of oral insulin. Diabetes. 2005;54(Suppl 1):A103.
14. Goldberg M, Dinh S, Castelli C, Majuru S, Arbit E. Improved glycemic control with oral recombinant human insulin in patients with type 2 diabetes (T2DM) inadequately controlled on metformin. Diabetes. 2007;56(Suppl 2):A121.
15. Clement S, Still JG, Kosutic G, McAllister RG. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther. 2002;4(4):459-66.
16. Kipnes M, Dandona P, Tripathy D, Still JG, Kosutic G. Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. Diabetes Care. 2003;26(2):421-6.
17. Wajcberg E, Miyazaki Y, Triplitt C, Cersosimo E, DeFronzo RA. Dose-response effect of a single administration of oral hexyl-insulin monoconjugate 2 in healthy nondiabetic subjects. Diabetes Care. 2004;27(12):2868-73.
18. Phillips J, Russel-Jones DL, Wright J, Brackenridge A, New R, Bansal G. Early evaluation of a novel oral insulin delivery system in healthy volunteers. Diabetes. 2004;53(Suppl 2):A113.
19. Luzio S, Dunseath G, Lockett A, Broke-Smith TP, New RR, Owens D. Comparison of an oral insulin (Capsulin) and Actrapid during an isoglycemic clamp study in persons with type 2 diabetes. Diabetes. 2008;56(Suppl 1):A10.
20. Broke-Smith TP, Luzio S, Lockett A, New RR, Owens DR. Repeat-dosing of oral insulin (Capsulin) in persons with type 2 diabetes. Diabetologia. 2008;51(Suppl 1):S8.
21. Davis SN, Geho B, Tate D, Galassetti P, Lau J, Granner D, Mann S. The effects of HDV-insulin on carbohydrate metabolism in type 1 diabetic patients. J Diabetes Complications. 2001;15(5):227-33.
22. Schwartz S, Geho B, Rosenberg L. Single-blind, placebo-controlled, dose-ranging trial of oral HDV-insulin in patients with type 2 diabetes mellitus. Diabetes. 2008;57(Suppl 1):A127.
23. Schwartz S, Geho B, Rosenberg L, Lau J. A 2-week randomized active comparator study of two HDV-Insulin routes (SC and oral) and SC human insulin in patients with type 1 diabetes. Diabetes. 2008;57(Suppl 1):A124.
24. Kidron M, Raz I, Schruefer C, Showb H, Wolfensberger M. Pharmacokinetics (PK) and pharmacodynamics (PD) or oral insulin in healthy subjects. Diabetes. 2008;57(Suppl 1):A127.
25. Faber-Heinemann G, Hess E, Hess G, von Hübbenet J, Kaltheuner M, Krakow D, Lederle M, Molinski M, Nitzsche G, Reuter HM, Scheper N, Simonsohn M, Heinemann L. Realität der Insulintherapie bei Typ 2 Diabetes in Deutschland: Daten aus 41 Schwerpunktpraxen. Diabetes, Stoffwechsel, und Herz. 2008;5:357-61.
26. Al-Waili NS. Sublingual human insulin for hyperglycaemia in type I diabetes. JPMA. 1999;49(7):167-9.
27. Bernstein G. Delivery of insulin to the buccal mucosa utilizing the RapidMist system. Expert Opin Drug Deliv. 2008;5(9):1047-55.
28. Cavallo MG, Coppolino G, Romero S, Pozzilli P. Inhaled insulin in type 1 diabetes. Lancet. 2001;357(9272):1980.
29. Modi P, Mihic M, Lewin A. The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist System. Diabetes Metab Res Rev. 2002;18 Suppl 1:S38-42.
30. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study. Diabetes Metab Res Rev. 2004;20(6):472-8.
31. Guevara-Aguirre J, Guevara M, Saavedra J, Mihic M, Modi P. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents. Diabetes Technol Ther. 2004;6(1):1-8.
32. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther. 2004;26(12):2084-91.
33. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I. Dose-response relationship of oral insulin spray in healthy subjects. Diabetes Care. 2005;28(6):1353-7.
34. Cernea S, Kidron M, Wohlgelernter J, Raz I. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study. Clin Ther. 2005;27(10):1562-70.
35. Pozzilli P, Manfrini S, Buzzetti R, Lampeter E, Leeuw ID, Iafusco D, Prisco M, Ionescu-Tirgoviste C, Kolouskovà S, Linn T, Ludvigsson J, Madàcsy L, Mrozikiewicz AS, Mrozikiewicz PM, Podar T, Vavrinec J, Vialettes B, Visalli N, Yilmaz T, Browne PD, IMDIAB Group. Glucose evaluation trial for remission (GETREM) in type 1 diabetes: a European multicentre study. Diabetes Res Clin Pract. 2005;68(3):258-64.
36. Guevara-Aguirre J, Guevara-Aguirre M, Saavedra J, Bernstein G, Rosenbloom AL. Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes. Diabetes Technol Ther. 2007;9(4):372-6.
37. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther. 2002;4(5):673-82.
38. Veuillez F, Kalia YN, Jacques Y, Deshusses J, Buri P. Factors and strategies for improving buccal absorption of peptides. Eur J Pharm Biopharm. 2001;51(2):93-109.